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Abstract
Background: In patients with myocardial infarction or heart failure, right ventricular (RV) dysfunction is associated with 
death, shock and arrhythmias. In patients with type 2 diabetes mellitus, structural and functional alterations of the left 
ventricle (LV) are highly prevalent, however, little is known about the impact of diabetes on RV characteristics. The 
purpose of the present study was to investigate whether LV changes are paralleled by RV alterations in a rat model of 
diabetes.
Methods: Zucker diabetic fatty (ZDF) and control (ZL) rats underwent echocardiography and positron emission 
tomography (PET) scanning using [18F]-2-fluoro-2-deoxy-D-glucose under hyperinsulinaemic euglycaemic clamp 
conditions. Glucose, insulin, triglycerides and fatty acids were assessed from trunk blood. Another group of rats 
received an insulin or saline injection to study RV insulin signaling.
Results: ZDF rats developed hyperglycaemia, hyperinsulinaemia and dyslipidaemia (all p < 0.05). Echocardiography 
revealed depressed LV fractional shortening and tricuspid annular plane systolic excursion (TAPSE) in ZDF vs. ZL rats 
(both p < 0.05). A decrease in LV and RV insulin-mediated glucose utilisation was found in ZDF vs. ZL rats (both p < 
0.05). LV associated with RV with respect to systolic function (r = 0.86, p < 0.05) and glucose utilisation (r = 0.74, p < 
0.05). TAPSE associated with RV MRglu (r = 0.92, p < 0.05) and M-value (r = 0.91, p < 0.0001) and RV MRglu associated 
with M-value (r = 0.77, p < 0.05). Finally, reduced RV insulin-stimulated phosphorylation of Akt was found in ZDF vs. ZL 
(p < 0.05).
Conclusions: LV changes were paralleled by RV alterations in insulin-stimulated glucose utilisation and RV systolic 
function in a rat model of diabetes, which may be attributed to ventricular interdependence as well as to the uniform 
effect of diabetes. Since diabetic patients are prone to develop diabetic cardiomyopathy and myocardial ischaemia, it 
might be suggested that RV dysfunction plays a central role in cardiac abnormalities in this population.
Background
Although been underestimated in the past, the contribu-
tion of right ventricular (RV) function to overall myocar-
dial contractility is considerable. RV dysfunction is
relevant in a variety of disease states, like pulmonary
hypertension, coronary heart disease and heart failure.
RV dysfunction is an independent predictor of outcome
in patients with myocardial infarction [1] and heart fail-
ure [2,3]. Patients with type 2 diabetes are at increased
risk of myocardial infarction [4], however, not much is
known on RV involvement in these patients.
While left ventricular (LV) impairment is a common
complication of type 2 diabetes mellitus (T2DM), the
number of studies focusing on the impact of T2DM on
RV function is limited and conflicting [5-8]. We [9] and
others [10,11] have shown that alterations in LV energy
metabolism, resulting from changes in substrate supply
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and utilisation, contribute to the development of myocar-
dial dysfunction, but this association has not been estab-
lished for the RV. Despite the association of RV
dysfunction with aggravation of myocardial function and
outcome in distinct cardiac diseases, its role in diabetic
cardiomyopathy is unknown. The purpose of the present
study was therefore to investigate whether LV changes are
paralleled by RV alterations with respect to glucose utili-
sation and function in an experimental rat model of dia-
betes.
Material and methods
Animals
All experiments were approved by the Animal Care and
Use Committee of the VU University, and were con-
ducted following the European Convention for the Pro-
tection of Vertebrate Animals used for Experimental and
Other Scientific Purposes, and the Dutch Animal Experi-
mentation Act.
Male Zucker diabetic fatty (ZDF) rats (fa/fa; n = 12,
Charles River Laboratories Brussels, Belgium) and age-
matched Zucker lean control rats (ZL; +/+; n = 10)
underwent echocardiography and positron emission
tomography (PET) at 14 weeks of age. Trunk blood was
collected for determinations of blood glucose, plasma
insulin, fatty acid and triglyceride levels [12]. Hearts were
removed and either snap-frozen in dry-ice-chilled iso-
pentane or fixed in 4% formalin for further biochemical
and histological analysis.
Echocardiography
Echocardiographic analyses were performed as previ-
ously described [9,12]. Measured parameters for RV
function were Doppler-derived cardiac output and tricus-
pid annular plane systolic excursion (TAPSE). Parameters
for RV remodeling and pulmonary vascular remodeling
were measured as RV end-diastolic diameter and pulmo-
nary artery acceleration time normalised for cycle length
(PAAT/cl), respectively [13]. Further, estimated RV sys-
tolic pressure (eRVSP) was determined by 142*e(-11*[PAAT/
cl]) [12].
Positron emission tomography
LV and RV glucose metabolism were measured using
[18F]-2-fluoro-2-deoxy-D-glucose (18FDG) PET under
hyperinsulinaemic euglycaemic clamp conditions, a gold-
standard estimate of whole-body insulin sensitivity [9].
Quantification was achieved with compartment analysis,
based on a two-tissue compartment model [9].
Histology
Sections of LV and RV were stained with hematoxylin-
eosin for determination of cardiomyocyte cross-sectional
area [12]. Picrosirius red staining was used for analysis of
myocardial fibrosis. LV and RV fibrosis were expressed as
the percentage tissue area positive for collagen, measured
over minimally three randomly chosen areas per ventricle
[13].
Western blotting
A separate group of rats (n = 4, ZDF rats; n = 4, ZL rats)
received insulin stimulation (10 U·kg-1 BW insulin) or
saline as control (n = 4, ZDF rats; n = 4, ZL rats) to study
RV insulin signaling [9,14] using the following primary
antibodies: phospho-Akt-Ser473, phospho-GSK3β-Ser9,
GSK3β (all Cell signaling Technology, Beverly, MA) and
Akt2 (Upstate, Lake Placid, NY).
RV substrate metabolism was studied using glucose
transporter 4 (GLUT4; Abcam, Cambridge, MA), phos-
pho-AMP activated protein kinase (AMPK)-Thr172,
AMPK (both Cell signaling Technology, Beverly, MA)
and pyruvate dehydrogenase kinase-4 (PDK4; Santa Cruz
Biotechnology, Santa Cruz, CA) [8]. All signals were nor-
malised to actin (Sigma, Saint Louis, Missouri) or total
protein expression.
Statistical analysis
All data are presented as mean ± SEM. Group compari-
sons were performed using student t-test or two-way
ANOVA with Bonferroni post-hoc analysis. Correlations
were calculated by the Pearson's test. p < 0.05 was consid-
ered as statistically significant.
Results
Consistent with a diabetic phenotype, ZDF rats were
obese, hyperglycaemic, hyperinsulinaemic and dyslipi-
daemic compared with ZL rats as shown in Table 1. The
clamp-measured M-value was significantly lower in ZDF
rats than in control rats (Table 1).
Echocardiography in ZDF rats showed a significant
decreased in RV and LV systolic function compared to
controls (Figure 1A and 1B), as measured by TAPSE and
fractional shortening, respectively. Cardiac output
remained unchanged in ZDF rats versus controls (96 ± 8
ml/min vs. 93 ± 6 ml/min for ZDF and ZL rats, respec-
tively, n.s.). TAPSE associated positively with LV frac-
tional shortening (r = 0.86, p < 0.05, Figure 1E).
Interestingly, RV diastolic diameter was significantly
increased, whereas LV diastolic diameter remained
unchanged (Figure 2A). Furthermore, PAAT/cl showed
no difference between the two experimental groups (0.17
± 0.01 for ZDF rats vs. 0.18 ± 0.01 for ZL rats, n.s.). Esti-
mated RVSP remained also unchanged between both
groups (21.2 ± 1.9 mmHg for ZDF rats vs. 23.6 ± 2.1
mmHg for ZL rats, n.s.).van den Brom et al. Cardiovascular Diabetology 2010, 9:25
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RV and LV metabolic rates of glucose utilisation
(MRglu) measured under hyperinsulinaemic euglycaemic
conditions were decreased by 66% and 60%, respectively,
in ZDF versus ZL rats (Figure 1C and 1D). RV MRglu was
positively associated with LV MRglu (r = 0.74, p < 0.05,
Figure 1F).
TAPSE associated significantly with RV MRglu (r =
0.92, p < 0.05) and M-value (r = 0.91, p < 0.0001) and RV
MRglu associated significantly with M-value (r = 0.77, p <
0.05).
RV weight, RV/(LV + septum) ratio, LV weight and lung
weight were similar in ZDF and ZL rats (data not shown).
Cross-sectional areas of individual RV cardiomyocytes
were similar between both groups, whereas cross section-
als areas of individual LV cardiomyocytes were signifi-
cantly increased (Figure 2B) in ZDF rats, suggesting
different remodeling between ventricles. Further, RV and
LV fibrosis remained unchanged between both groups
(Figure 2C).
Phosphorylation of Akt and GSK3β were studied to
determine RV insulin sensitivity. ZDF and ZL hearts
showed similar basal Akt and GSKβ phosphorylation. RV
insulin-dependent phosphorylation of Akt-Ser473 was
decreased in ZDF rats (two-way ANOVA interaction p =
0.05, Figure 3A and 3C). Further, insulin injection
increased GSK3β phosphorylation significantly in ZL
rats, but this increase was blunted in ZDF rats (Figure 3B
and 3D).
Glucose transporter 4 (GLUT4) and AMP-activated
kinase (AMPK) protein expression was decreased in ZDF
r a t s  c o m p a r e d  t o  Z L  r a t s ,  h o w e v e r ,  G L U T 4  f a i l e d  t o
reach significance (p = 0.09, Figure 3E, F and 3H). Fur-
ther, pyruvate dehydrogenase kinase 4 (PDK4) protein
expression remained unchanged between the groups
(Figure 3G).
Discussion
Using echocardiography and 18FDG PET, the main find-
ing of this study was that diabetic cardiomyopathy in an
experimental model of diabetes is characterised by RV
and LV alterations. In particular, changes in RV function
were associated with systemic insulin sensitivity and
reduced RV insulin-stimulated glucose utilisation. The
alterations in RV and LV insulin-stimulated glucose
metabolism and systolic function may be attributed to
ventricular interdependence, but also indicate that diabe-
tes similarly affects both ventricles.
Impaired RV systolic function as reported in the pres-
ent study is in agreement with data from Mittal [5] and
Movahed et al. [8] who reported comparable results in
T2DM patients. Others showed deterioration of RV dia-
stolic function in these patients, whereas the association
with RV systolic dysfunction was undecided ambivalent
[6,7,15]. In addition, the metabolic alterations in the RV
as found in the present study are consistent with previ-
ously reported findings in 18FDG PET studies of the LV in
ZDF rats [9,16].
A restriction to glucose utilisation in the diabetic heart
is the slow rate of glucose transport [17]. In line with pre-
vious reports of the LV [9,18,19], decreased GLUT4
expression was found, which is compatible with the in
vivo  change in RV insulin-stimulated glucose metabo-
lism. Impaired insulin signaling is associated with altera-
tions in glucose metabolism. Impaired systemic and RV
insulin sensitivity was demonstrated by hyperinsulinae-
mic euglycaemic clamp and an impaired ability of insulin
to phosphorylate Akt and GSK3β. Overall these molecu-
lar analyses are in line with the molecular changes found
in the LV [9], suggesting the uniform effect of diabetes on
the heart. Finally, an association was found between RV
and LV changes with respect to systolic function and glu-
cose metabolism.
Table 1: Characteristics of ZL (+/+) and ZDF (fa/fa) rats at 14 weeks of age
ZL ZDF
Body weight at killing [g] 335 ± 4 355 ± 8*
Non-fasting blood glucose [mmol·L-1] 5.0 ± 0.1 20.9 ± 0.8*
Fasting insulin [pmol·L-1] 116.9 ± 11.9 330.7 ± 69.6*
Fasting triglycerides [mmol·L-1] 0.36 ± 0.02 1.41 ± 0.20*
Fasting fatty acids [mmol·L-1] 0.16 ± 0.03 0.38 ± 0.08*
M-value [mg·kg·min-1] 22.4 ± 1.0 8.9 ± 0.8*
Data are expressed as mean ± SEM, n = 8, * p < 0.05 vs. ZL
ZL, Zucker lean; ZDF, Zucker diabetic fattyvan den Brom et al. Cardiovascular Diabetology 2010, 9:25
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Remodeling of the ventricles was found to be different
despite comparable changes in function and metabolism
between the ventricles. Despite the absence of fibrosis in
both ventricles, LV remodeling in ZDF rats is indicated
by hypertrophy of individual cardiomyocytes in the
absence of L V dilatation. In contrast, RV remodeling in
ZDF rats is indicated by dilatation of the RV in the
absence of hypertrophy. This is in agreement with Kos-
mala et al. [7] who reported the absence of changes in RV
free wall thickness.
Figure 1 In vivo alterations in right and left ventricular glucose metabolism and function. Relative change in systolic function of RV (tricuspid 
annulus systolic plane excursion; TAPSE) (A) and LV (fractional shortening) (B) and metabolic rate of glucose utilisation (MRglu) measured under hy-
perinsulinaemic euglycemic clamp conditions for RV (C) and LV (D) of ZL rats (white bars) and ZDF rats (black bars). Data are expressed as mean ± SEM, 
n = 4-9, * p < 0.05 vs. ZL rats. Relationship of RV systolic function (TAPSE) with LV systolic function (fractional shortening) (E; r = 0.86, p < 0.05, n = 11) 
and RV MRglu with LV MRglu (F; r = 0.74, p <0.05, n = 10).
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Briefly, the following mechanisms can be hypothesized:
1) increased L V filling pressure is translated to the pul-
monary circulation, 2) ventricular interdependence and
3) both ventricles are exposed to the metabolic abnormal-
ities characterising T2DM. Measurements on afterload
and RV remodeling remained unchanged; we can there-
fore conclude that there are no differences in pulmonary
vascular resistance. Based on the geometry of the heart it
is expected that there is ventricular interdependence.
However, in a model of diet-induced obesity, impaired LV
function in the absence of RV dysfunction was found
(data not shown), which suggests that the effect of diabe-
tes on RV function may be of greater importance than
previously assumed. In combination with the in vivo and
molecular changes found in RV glucose metabolism and
insulin signaling, this suggests that diabetes affects both
ventricles.
Collectively, diabetes seems to affect RV glucose
metabolism and RV systolic function in similar propor-
tions as in the LV, which could be due to ventricular inter-
dependence as well as the uniform effect of diabetes on
the heart.
Conclusion
Whereas consequences of diabetes on the heart were pre-
viously restricted to the LV, this study showed that LV
insulin-stimulated glucose utilisation and LV systolic
function are paralleled by significant alterations in RV
insulin-stimulated glucose utilisation and RV function in
an experimental rat model of diabetes. RV dysfunction is
associated with worse outcome in a variety of cardiovas-
cular diseases, including myocardial infarction and heart
failure. The negative association of RV function with
prognosis has only been scarcely investigated in the dia-
betic population. However, since diabetic patients are
prone to develop diabetic cardiomyopathy and myocar-
dial ischaemia [4], it might be suggested that RV dysfunc-
tion plays a central role in cardiac abnormalities in this
population. This warrants further research with respect
to the role of RV function in diabetic cardiomyopathy and
its relation to patient outcome in diabetes.
Figure 2 Dilatation of the right ventricle and hypertrophy in the left ventricle. Diastolic diameter of RV and LV (A), cross sectional area of indi-
vidual cardiomyocytes in RV and LV (B) and quantification of fibrosis (C) of ZL rats (white bars) and ZDF rats (black bars). Data are expressed as mean 
± SEM, n = 4-9, * p < 0.05 vs. ZL rats.
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Figure 3 Molecular changes in right ventricular insulin signaling. Immunoblots showing Akt (A) and glycogen synthase kinase (GSK)3β (B) and 
glucose transporter (GLUT)4, pyruvate dehydrogenase kinase (PDK)4 and AMP activated kinase (AMPK) (E). Quantification of immunoblots showing 
relative phosphorylation of Akt (C) and GSK3β (D) after saline (-; open bars) or insulin (+; filled bars) injection in RV. Quantification of immunoblots 
showing relative protein expression of GLUT4 (F), PDK4 (G) and AMPK phosphorylation (H) in ZL rats (white bars) and ZDF rats (black bars). Data are 
expressed as mean ± SEM, n = 4, * p < 0.05 vs. ZL rats, $ p = 0.09 vs. ZL rats, # p < 0.05 insulin vs. saline effect.
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